Deerfield Management Company, L.P.'s Form 4 filing
Mirum Pharmaceuticals, Inc. (MIRM) · filed Jul 7, 2021
- Accession no.
- 0001193805-21-000999
- Filed
- Jul 7, 2021, 6:48 PM ET
- Trade date
- Jul 2-7, 2021
- Filing delay
- 5 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 3 non-derivative transactions. Open-market sales total $1.09M. It was filed 5 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Deerfield Management Company, L.P.CIK 0001009258 | 10% Owner, Other: * Possible Member of 10% Group |
| Deerfield Mgmt L.P.CIK 0001010823 | 10% Owner, Other: * Possible Member of 10% Group |
| Flynn James ECIK 0001352546 | 10% Owner, Other: * Possible Member of 10% Group |
| Deerfield Special Situations Fund, L.P.CIK 0001354395 | 10% Owner, Other: * Possible Member of 10% Group |
| Deerfield Healthcare Innovations Fund, L.P.CIK 0001646981 | 10% Owner, Other: * Possible Member of 10% Group |
| Deerfield Mgmt HIF, L.P.CIK 0001665736 | 10% Owner, Other: * Possible Member of 10% Group |
| Deerfield Private Design Fund IV, L.P.CIK 0001680307 | 10% Owner, Other: * Possible Member of 10% Group |
| Deerfield Mgmt IV, L.P.CIK 0001713467 | 10% Owner, Other: * Possible Member of 10% Group |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jul 2, 2021 | Common Stock | SSaleDisposed | −10,599 | $17.01F1 | −$180,299.59 | 155,401 | Indirect | |
| Jul 6, 2021 | Common Stock | SSaleDisposed | −49,239 | $16.20F2 | −$797,425.61 | 106,162 | Indirect | |
| Jul 7, 2021 | Common Stock | SSaleDisposed | −6,837 | $15.87F3 | −$108,496.35 | 99,325 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The price reported in Column 4 represents a weighted average price. The shares were sold in multiple transactions at prices ranging from $16.85 to $17.55, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 1 and 2 of this Form 4.
Referenced by the price of 1 transaction in Table I.
- F2
The price reported in Column 4 represents a weighted average price. The shares were sold in multiple transactions at prices ranging from $16.185 to $16.345, inclusive.
Referenced by the price of 1 transaction in Table I.
- F3
The price reported in Column 4 represents a weighted average price. The shares were sold in multiple transactions at prices ranging from $15.84 to $15.955, inclusive.
Referenced by the price of 1 transaction in Table I.
Remarks
Jonathan Isler, Attorney-in-Fact: Power of Attorney, which is hereby incorporated by reference to Exhibit 24 to a Form 3 with regard to Proteon Therapeutics, Inc. filed with the Securities and Exchange Commission on August 4, 2017 by Deerfield Special Situations Fund, L.P., Deerfield Partners, L.P., Deerfield International Master Fund, L.P., Deerfield Private Design Fund III, L.P., Deerfield Private Design Fund IV, L.P., Deerfield Mgmt, L.P., Deerfield Mgmt III, L.P., Deerfield Mgmt IV, L.P., Deerfield Management Company, L.P., and James E. Flynn.